

# FluCov Influenza Activity Report #21


15 April 2024

## Take home: decreasing influenza activity in the Northern Hemisphere

- North America and Europe:** Influenza activity is decreasing in the United States, with minimal to low activity in most states, although one state (ND) still experiences high activity. In Europe, influenza activity continued to decrease and has returned to baseline levels in most countries. In week 14/2024, Denmark, Spain and the UK report very low activity (<10% positivity), and Germany reports low activity (10-20% positivity rate).
- Asia:** Influenza detections decreased in China. Overall positivity rate also decreased in week 14/2024, compared to week 13, with very low activity (8% positivity) in Northern China and low activity (13% positivity) in Southern China.
- Circulating virus:** Globally, all seasonal influenza viruses except B/Yamagata are circulating. While B/Victoria predominated in China and Canada, A(H1N1)pdm09 dominated circulation in Europe. Currently, influenza A(H1N1)pdm09m A(H3N2) and B viruses are all co-circulating in the United States (CDC).
- Vaccine match:** US (CDC) reports that vaccine components are well-matched to circulating A(H1N1)pdm09, B/Victoria and A(H3) clades. The same is true for Europe (ECDC) with the exception that some A(H3) viruses (2a.3a.1 clade) are less well-matched (ERVISS).
- Influenza Viruses of Pandemic Potential:** No IVPP events of note reported this week. Recent studies indicate clade 2.3.4.4b from Chile human H5N1 case resulted in ferret fatalities & co-housed ferret transmission (CDC/EID & Canada/pre-published).
- COVID hospitalizations:** Continued to decrease in the EU, England and the US, after a peak around the end of 2023.


## Positive Influenza tests (%)

— Season 2023/2024   
 — Season 2022/2023   
 — Season 2021/2022   
 — Average of pre-COVID-19 seasons (2014/2015 to 2018/2019) [Min; Max]



## Weekly COVID-19 hospital admissions

(England, EU/EEA, US – admissions/100,000)



Displayed data is the most recent reported; it is possible that there may be a delay in reporting. Countries & inclusion dates for EU/EEA data vary markedly each week.

### Data sources & details

China:	China CDC
US:	FluView (Clinical Laboratories)
Spain:	ERVISS
DK:	WHO FluNET (non-sentinel)
All others:	WHO FluNet (sentinel)
COVID:	US (Department of Health and Human Services), EU (ERVISS), England (UKHSA)
Vaccine match:	US (CDC), EU (ERVISS)

### A Nivel publication

FluCov team: Susanne Heemskerk, Bronke Boudewijns, Marco Del Riccio, Daan van Kooten, Saverio Caini, Caroline Schneeberger.

[FluCov Influenza Activity Report #21: 15 April 2024](#). Netherlands, Utrecht: Nivel, 2024

### Websites for more information

Project Website: <https://www.nivel.nl/en/flucoV>

FluCoV Dashboard: <https://www.nivel.nl/en/flucoV-dashboard>

### Funding

The Nivel FluCov project is funded by Sanofi